APA (7e ed.) Bronvermelding

Morgensztern, D., Cobo, M., Ponce Aix, S., Postmus, P., Lewanski, C., Bennouna, J., . . . Investigators, O. B. O. T. A. L. (2018). ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC). Wiley.

Chicago (17e ed.) Bronvermelding

Morgensztern, D., et al. ABOUND.2L+: A Randomized Phase 2 Study of Nanoparticle Albumin‐bound Paclitaxel with or Without CC‐486 as Second‐line Treatment for Advanced Nonsquamous Non‐small Cell Lung Cancer (NSCLC). Wiley, 2018.

MLA (9e ed.) Bronvermelding

Morgensztern, D., et al. ABOUND.2L+: A Randomized Phase 2 Study of Nanoparticle Albumin‐bound Paclitaxel with or Without CC‐486 as Second‐line Treatment for Advanced Nonsquamous Non‐small Cell Lung Cancer (NSCLC). Wiley, 2018.